Clinical Trial Update: Efficacy and Safety Study With MYL-1401H and Neulasta [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating efficacy and safety of MYL-1401H with Neulasta in breast cancer patients with chemotherapy-induced febrile neutropenia; study co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Chemotherapy-induced Febrile Neutropenia

Drugs mentioned

• MYL-1401H (MYL-1401H)
• NEULASTA (pegfilgrastim)

Snippet

Sponsor: Mylan Inc. | Conditions: Breast Neoplasms, Chemotherapy-Induced Febrile Neutropenia | Phase 3 | Status: COMPLETED